The Pharmaceutical Sprint: Speed of Innovation Deployment

3 June, 10:00–11:30 Congress Centre, zone B, 2nd floor, conference hall B3
In the current strategic planning landscape, the effectiveness of the healthcare system is dictated not by the volume of drug packages purchased, but rather by the clinical and economic value that the drugs provide to patients and the industry as a whole. Current rules governing the compilation of restrictive lists are creating various barriers to innovative developments that are both intrinsic in some cases and excessive in others. A fundamental component of the strategic approach to ensuring the accessibility of advanced treatments in clinical practice could be a paradigm shift regarding the introduction of innovations and a transition toward a differentiated model for assessing the value of medicinal products. The introduction of fast-track mechanisms for drugs that are in high medical demand and the compilation of a roadmap for integrating socioeconomic criteria into regulatory practices to assess the anticipated value of drugs could provide a transparent pathway for innovation, from the laboratory to the patient, while simultaneously preserving the financial sustainability of the healthcare system. What tools and mechanisms for the effective introduction of in-demand innovative solutions could help reduce the time required to deliver them to patients? How promising and crucial for the industry is the introduction of a fast-track mechanism for new technologies, as well as the granting of a pre-inclusion status in the List of Vital and Essential Medicines for drugs with exceptional significance? What flexible price regulation and procurement models could optimize mechanisms used to manage drug expenditures? What is the main point of the strategic shift from cost management to value management, and how is the model for assessing the expected value of drugs creating a new architecture for innovation accessibility?